Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juergen Harting is active.

Publication


Featured researches published by Juergen Harting.


Journal of Cardiovascular Pharmacology | 1991

The novel cardiotonic agent EMD 53 998 is a potent calcium sensitizer

Norbert Beier; Juergen Harting; Rochus Jonas; Michael Klockow; Inge Lues; G. Haeusler

EMD 53 998, a novel thiadiazinone derivative, increases the contractile force of cardiac tissue in vitro through both an inhibition of phosphodiesterase III (PDE III) and a sensitization of cardiac contractile proteins to Ca2+. Guinea pig ventricular PDE III is selectively inhibited by EMD 53 998 (IC50 = 60 nM) without major effects on other PDE isoenzymes. Consonant with this is an increase in cAMP content of rat ventricular cells and a potentiation by EMD 53 998 of the cAMP-elevating action of isoprenaline (increase by 50% at 1.3 μM). Sensitization to Ca2+ by EMD 53 998 (3–30 μM) finds its expression in a leftward shift of the Ca2+ response curve for force generation in skinned fibers from porcine ventricular muscle and failing human heart as well as for activation of bovine cardiac myofibrillar actomyosin ATPase. Interestingly, EMD 53 998 elevates the maximum of the Ca2+ -response curve for both parameters. Pimobendan studied under identical conditions was 100 times less potent than EMD 53 998. EMD 53 998 increases force development of guinea pig papillary muscle in a concentration-dependent manner with an EC50 of 3.6 μM. thus being 10 times more potent than pimobendan. In contrast to pimobendan, the positive inotropic effect of EMD 53 998 is barely affected by carbachol. Further evidence for a Ca2+ -sensitizing effect of EMD 53 998 is provided by an additional increase in force generation in the presence of supramaximal isoprenaline concentrations. It is concluded that the positive inotropic action of EMD 53 998 is mediated through both cAMP-independent and cAMP-dependent mechanisms, with the former probably prevailing. We are not aware of other compounds with a similarly high Ca2+ -sensitizing potency. On these grounds, EMD 53 998 appears to be a promising inotropic agent.


Neurobiology of Aging | 1985

Drug induced hypothermia in adult and senescent rats

James R. Martin; Andreas Fuchs; Juergen Harting

Temperature regulation was evaluated in senescent (34-40 month old) and adult (8-9 month old) female Iva:WIWU and Emd:Wi-AF/Han rats. Injection of 1.5 mg/kg BW apomorphine HCl or 1.0 mg/kg BW oxotremorine sesquifumarate produced comparable maximal hypothermic responses in adult and senescent rats. However, the latency to reach maximal hypothermia after oxotremorine (but not apomorphine) was longer in senescent than in adult rats of both strains.


Neurobiology of Aging | 1985

Drinking by senescent and adult rats in response to regulatory challenges

James R. Martin; Andreas Fuchs; Juergen Harting

The regulation of water and electrolyte balance was elevated in senescent (greater than 31 months) and adult (5-10 months) rats of several strains. Weekly food and water intake, drinking induced by 24-hr water deprivation and drinking induced by injection of hypertonic saline were roughly the same in old and adult rats. However, senescent rats drank less after injection of the beta-adrenergic agonist isoprenaline than adult rats. There were no appreciable strain differences in drinking in response to these regulatory challenges although baselines sometimes differed between strains.


Archive | 1998

Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands

Christoph Van Amsterdam; Hartmut Greiner; Henning Boettcher; Gerd Bartoszyk; Juergen Harting; Lisa Matzen; Wilfried Rautenberg


Archive | 2004

N-(indolecarbonyl) piperazine derivatives

Henning Boettcher; Hartmut Greiner; Juergen Harting; Gerd Bartoszyk; Christoph Seyfried; Christoph Van Amsterdam


Archive | 1983

2-Aryltetraazaindenes for treating cardiac insufficiency

Rochus Jonas; Michael Kloft; Hanns Wurziger; Juergen Harting; Hans J. Enenkel; Klaus-Otto Dr. Minck; Hans-Jochen Dr Schliep


Archive | 1997

New indole amide derivatives

Lisa Matzen; Christoph Van Amsterdam; Hartmut Dr Greiner; Wilfried Rautenberg; Henning Boettcher; Gerd Bartoszyk; Juergen Harting


Archive | 1996

1- (pyrazol-4-indol-3-yl) -piperidines

Henning Boettcher; Joachim Dr Maerz; Gerd Bartoszyk; Hartmut Dr Greiner; Juergen Harting; Christoph Dr Seyfried


Archive | 2001

Heterocyclic aminoalkylpyridine derivatives as psychopharmaceuticals

Dieter Dorsch; Henning Boettcher; Michael Arlt; Christoph Seyfried; Gerd Bartoszyk; Juergen Harting; Rudolf Gottschlich


Archive | 2000

New piperidine and piperazine derivatives which are antagonists of certain serotonin receptors, are useful in treatment of, e.g. eating disorders, stroke, anxiety or Parkinson's disease

Karl-August Ackermann; Henning Boettcher; Helmut Pruecher; Christoph Van Amsterdam; Christoph Seyfried; Hartmut Greiner; Gerd Bartoszyk; Juergen Harting

Researchain Logo
Decentralizing Knowledge